Drugs / second generation 4 1BBζ CD19-Her2tG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04483778 | Jul 2020 → Dec 2040 expected | Ewing sarcoma, Wilms tumor, childhood malignant neoplasm, clear cell sarcoma +11 | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03618381 | Jun 2019 → Jun 2040 expected | Ewing sarcoma, Wilms tumor, childhood malignant neoplasm, clear cell sarcoma +10 | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | second generation 4-1BBζ CD19-Her2tG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04483778 ↗ |
| Modality | Cell therapy | “Autologous CD4 and CD8 T cells lentivirally transduced” NCT03618381 ↗ |
| Target | CD19 | “research participants will receive CAR T cells directed at EGFR and CD19, a marker on the surface of B lymphocytes” NCT03618381 ↗ |